MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-05-2026
Neurocrine Biosciences EV/EBITDA Ratio 2011-2026 | NBIX
Annual EV/EBITDA Ratio Neurocrine Biosciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 69.1 | 29.3 | 41 | 198 | -60.3 | -23.3 | -37.8 | -39 | -22.5 | 244 | 13.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 244 | -60.3 | 37.5 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-0.271 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M |  Germany |
 |
Coherus BioSciences
CHRS
|
-1.86 | $ 1.57 | -3.68 % | $ 184 M |  USA |
 |
Happiness Biotech Group Limited
HAPP
|
-0.984 | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
11.2 | $ 16.87 | -2.49 % | $ 789 M | USA |
 |
AgeX Therapeutics
AGE
|
-0.164 | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
595 | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
4.22 K | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
3.06 | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-0.593 | $ 7.47 | -4.6 % | $ 205 M |  Israel |
 |
Athira Pharma
ATHA
|
0.0485 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
8.55 | - | 0.74 % | $ 768 M | Israel |
 |
Eton Pharmaceuticals
ETON
|
187 | $ 30.26 | 1.0 % | $ 814 M | USA |
 |
Galera Therapeutics
GRTX
|
2.25 | - | -32.59 % | $ 7.61 M | USA |
 |
Exelixis
EXEL
|
18.1 | $ 50.13 | -1.9 % | $ 13.6 B | USA |
 |
Fortress Biotech
FBIO
|
-1.74 | $ 2.41 | 4.78 % | $ 67.2 M | USA |
 |
Midatech Pharma plc
MTP
|
0.204 | - | -18.52 % | $ 27.3 M | Britain |
|
Forte Biosciences
FBRX
|
-3.97 | $ 23.11 | -3.55 % | $ 299 M | USA |
 |
AbCellera Biologics
ABCL
|
-6.16 | $ 4.09 | -7.05 % | $ 1.22 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
-2.4 | $ 1.63 | 2.52 % | $ 434 M | Britain |
 |
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - |  Russia |
 |
BioNTech SE
BNTX
|
-12.2 | $ 89.55 | -2.65 % | $ 21.6 B | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
-0.0315 | - | - | $ 231 M | USA |
 |
Galectin Therapeutics
GALT
|
-1.92 | $ 2.17 | -7.66 % | $ 139 M | USA |
 |
Celyad Oncology SA
CYAD
|
0.0447 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-1.29 | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
-0.5 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-3.88 | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-10.5 | - | - | $ 3.67 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-0.142 | - | - | $ 7.46 M | Israel |
 |
Gilead Sciences
GILD
|
16.9 | $ 129.58 | -1.88 % | $ 161 B | USA |
 |
Advaxis
ADXS
|
0.084 | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
0.0726 | $ 3.36 | -3.72 % | $ 5.53 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-0.963 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-7.74 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.268 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-45.5 | - | 1.93 % | $ 17.4 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
-1 | $ 0.72 | -1.58 % | $ 32.9 M | Israel |
 |
Esperion Therapeutics
ESPR
|
19.2 | $ 3.12 | - | $ 649 M | USA |
 |
Aptose Biosciences
APTO
|
1.65 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Genmab A/S
GMAB
|
2.7 | $ 26.54 | -1.34 % | $ 1.72 B |  Danmark |
 |
Aptinyx
APTX
|
0.293 | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-1.13 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-3.38 | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
1.19 | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-0.000271 | - | - | $ 28.6 M | USA |